Intravenously administered tissue plasminogen activator (IV-TPA) induces thrombolysis and remains the only FDA-approved therapy for acute ischaemic stroke (IS) within the therapeutic time-window according to the current guidelines. However, significantly low recanalisation rates have been demonstrated with intravenous thrombolysis alone.
This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.
